One approach to testing whether ErbB2 downregulates Irf6 in human breast cancer is to examine whether therapies based on the use of a therapeutic anti-ErbB2 antibody trastuzumab upregulate Irf6 in patients’ tumors. Here, IRF6 is linked to breast cancer.